CD59 expression and complement susceptibility of human neuronal cell line (NTera2)

NeuroReport

Volumn 7, Issue 5, 1996, Pages 997-1004

  Agoropoulou, C ^a   Wing, M G ^a   Wood, A ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

C3b; CD59; Complement; Complement inhibitors; DAF; Glycolipid anchored proteins; Intracellular calcium; NTera2

Indexed keywords

CALCIUM ION; CD59 ANTIGEN; COBROTOXIN; COMPLEMENT COMPONENT C3B; GLYCOLIPID; REGULATOR PROTEIN;

ALZHEIMER DISEASE; ANTIGEN EXPRESSION; ARTICLE; CELL LINE; CELL VIABILITY; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; MULTIPLE SCLEROSIS; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; PARKINSON DISEASE; PRIORITY JOURNAL; STEM CELL;

EID: 0029920046     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199604100-00009     Document Type: Article

References (29)

1. Davies A. Simmons DL, Hall G et al. J Exp Med 170, 637-654 (1989).
2. Meri S, Morgan BP, Davies A et al. Immunology 71, 1-9 (1990).
3. Tada T, Okada H, Okada N et al. J Histochem Cytochem 41, 119-122 (1993).
4. Vedeler C, Ulvestad E, Bjorge L et al. Immunology 82, 542-547 (1994).
5. Kumar S, Vinci JM, Pytel VA et al. Cancer Res 53, 348-353 (1993).
6. Zajicek J, Wing M, Skepper J et al. Lab Invest 73, 128-138 (1995).
7. Yamada T, McGeer PL and McGeer EG. Acta Neuropathol 84, 100-104 (1992).
8. Morgan BP, Cambell AK and Compston DA. Lancet ii, 251-254 (1984).
9. Compston DA, Morgan BP, Campbell AK et al. Neuropathol Appl Neurobiol 15, 307-316 (1989).
10. Gay D and Esiri M. Brain 114, 557-572 (1991).
11. McGeer PL, Akiyama H, Itagaki S et al. Neurosci Lett 107, 341-346 (1989).
12. Zhan SS, Veerhuis R, Janssen I et al. Neurodegeneration 3, 111-117 (1994).
13. Brachova K, Lue LF, Schulta J et al. Mol Brain Res 18, 329-334 (1993).
14. McGeer PL, Walker DG, Akiyama H et al. Brain Res 544, 315-319 (1991).
15. Rogers J, Cooper NR, Webster S et al. Proc Natl Acad Sci USA 89, 10016-10020 (1992).
16. Pleasure SJ and Lee VM. J Neurosci Res 35, 585-602 (1993).
17. Wing MG, Zajicek J, Seilly DJ et al. Immunology 76, 140-145 (1992).
18. Walker DG and McGeer PL. Mol Brain Res 14, 109-116 (1992).
19. Dietzschold B, Schwaeble W, Schafer MKH et al. J Neurol Sci 130, 11-16 (1995).
20. Broadwell RD and Sofroniew MV. Exp Neurol 120, 245-263 (1993).
21. Graeber MB, Streit WJ and Kreutzberg GW. J Neurosci Res 21, 18-24 (1988).
22. Wood A, Wing MG, Benham CD et al. J Neurosci 13, 3319-3332 (1993).
23. Scolding NJ, Morgan BP, Houston A et al. J Neurol Sci 89, 289-300 (1989).
24. Wren DR and Noble M. Proc Natl Acad Sci USA 86, 9025-9029 (1989).
25. Zajicek J, Wing MG, Lachmann PJ et al. J Neurol Sci 108, 65-72 (1992).
26. Piddlesden SJ and Morgan BP. J Neuroimmunol 48, 169-175 (1993).
27. Shen Y, Halperin JA and Lee CM. Brain Res 671, 282-292 (1995).
28. Brooimans RA, Van Wieringen PA, Van Es LA et al. Eur J Immunol 22, 3135-3140 (1992).
29. Johnson SA, Pasinetti GM and Finch CE. Dev Brain Res 80, 163-174 (1994).